Complete financial analysis of Tatva Chintan Pharma Chem Limited (TATVA.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tatva Chintan Pharma Chem Limited, a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- InnoCan Pharma Corporation (INNO.CN) Income Statement Analysis – Financial Results
- RDVA, Inc. (RDVA) Income Statement Analysis – Financial Results
- Braskem S.A. (BRKM5.SA) Income Statement Analysis – Financial Results
- Semapa – Sociedade de Investimento e Gestão, SGPS, S.A. (SEM.LS) Income Statement Analysis – Financial Results
- Dr. Ing. h.c. F. Porsche AG (DRPRF) Income Statement Analysis – Financial Results
Tatva Chintan Pharma Chem Limited (TATVA.NS)
About Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited manufactures and sells specialty chemicals in India. The company offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor batteries; and pharmaceutical APIs, agrochemical products, and other specialty chemicals in the form of intermediates, disinfectants, catalysts, and solvents. It also provides quaternary compounds and quats, and bulk drugs, as well as trading of specialty chemicals. It serves various industries, including the automotive, petroleum, pharmaceutical, agro-chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrances industries. The company also exports its products to approximately 25 countries. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 3.90B | 4.24B | 4.31B | 2.97B | 2.58B | 2.02B | 1.34B |
| Cost of Revenue | 3.20B | 2.26B | 2.08B | 1.55B | 1.38B | 1.16B | 1.02B |
| Gross Profit | 700.68M | 1.98B | 2.24B | 1.41B | 1.19B | 861.48M | 321.59M |
| Gross Profit Ratio | 17.94% | 46.63% | 51.85% | 47.63% | 46.28% | 42.55% | 24.05% |
| Research & Development | 79.42M | 60.39M | 37.07M | 2.79M | 10.14M | 1.99M | 1.89M |
| General & Administrative | 58.90M | 50.67M | 43.84M | 22.93M | 22.74M | 39.53M | 0.00 |
| Selling & Marketing | 225.13M | 287.66M | 338.26M | 191.88M | 170.23M | 159.21M | 0.00 |
| SG&A | 219.26M | 404.76M | 382.10M | 214.81M | 192.97M | 198.74M | 132.62M |
| Other Expenses | 0.00 | 57.44M | 1.33M | 4.50M | 453.13M | 390.00K | -2.04M |
| Operating Expenses | 642.47M | 1.46B | 1.23B | 807.89M | 656.24M | 541.05M | 136.55M |
| Cost & Expenses | 3.51B | 3.73B | 3.31B | 2.36B | 2.04B | 1.70B | 1.15B |
| Interest Income | 23.96M | 41.59M | 45.49M | 3.59M | 5.17M | 2.71M | 0.00 |
| Interest Expense | 61.51M | 84.04M | 42.32M | 39.85M | 37.52M | 32.98M | 19.38M |
| Depreciation & Amortization | 256.05M | 95.55M | 81.80M | 67.32M | 47.93M | 40.18M | 29.52M |
| EBITDA | 756.71M | 626.96M | 1.17B | 717.71M | 566.19M | 353.39M | 245.96M |
| EBITDA Ratio | 19.38% | 15.66% | 27.04% | 24.08% | 21.82% | 16.77% | 16.05% |
| Operating Income | 422.17M | 584.69M | 1.00B | 601.81M | 532.50M | 317.00M | 185.04M |
| Operating Income Ratio | 10.81% | 13.80% | 23.30% | 20.27% | 20.66% | 15.66% | 13.84% |
| Total Other Income/Expenses | 13.51M | -131.56M | -923.59M | -546.35M | -60.24M | -46.50M | 5.30M |
| Income Before Tax | 435.68M | 447.79M | 1.04B | 606.96M | 475.97M | 273.93M | 190.34M |
| Income Before Tax Ratio | 11.16% | 10.57% | 24.14% | 20.45% | 18.47% | 13.53% | 14.24% |
| Income Tax Expense | 132.14M | -7.08M | 82.47M | 84.34M | 98.08M | 68.50M | 67.45M |
| Net Income | 303.54M | 454.87M | 958.74M | 522.62M | 377.89M | 205.43M | 122.89M |
| Net Income Ratio | 7.77% | 10.74% | 22.23% | 17.61% | 14.66% | 10.15% | 9.19% |
| EPS | 13.26 | 20.52 | 44.59 | 26.02 | 18.81 | 10.23 | 6.12 |
| EPS Diluted | 13.26 | 20.52 | 44.59 | 26.02 | 18.81 | 10.23 | 6.12 |
| Weighted Avg Shares Out | 22.89M | 22.17M | 21.50M | 20.09M | 20.09M | 20.09M | 20.09M |
| Weighted Avg Shares Out (Dil) | 22.89M | 22.17M | 21.50M | 20.09M | 20.09M | 20.09M | 20.09M |
Source: https://incomestatements.info
Category: Stock Reports